# Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

> **NCT01752985** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 319 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** BMS-813160
- **DRUG:** Placebo matching with BMS-813160

## Key facts

- **NCT ID:** NCT01752985
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-18
- **Primary completion:** 2015-06-30
- **Final completion:** 2015-06-30
- **Target enrollment:** 319 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752985, "Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01752985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*